These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24854977)

  • 1. Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents.
    Goldenberg RM
    Can J Diabetes; 2011 Dec; 35(5):518-27. PubMed ID: 24854977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure-lowering effects of incretin-based diabetes therapies.
    Lovshin JA; Zinman B
    Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in incretin-based therapies.
    Russell-Jones D; Gough S
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):489-99. PubMed ID: 22804841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New developments in incretin-based therapies: the current state of the field.
    Robertson C
    J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():631-41. PubMed ID: 19900194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
    Pi-Sunyer FX
    Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatments in type 2 diabetes: a focus on the incretin-based therapies.
    Barnett AH
    Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New.
    Goldenberg RM; Berall M; Chan CTM; Cherney DZI; Lovshin JA; McFarlane PA; Senior PA; Verma S; Weinstein JJ
    Can J Diabetes; 2018 Jun; 42(3):325-334. PubMed ID: 28822777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
    Madsbad S; Krarup T; Deacon CF; Holst JJ
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus.
    Zarowitz BJ; Conner C
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):55S-67S. PubMed ID: 19947817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
    Drab SR
    Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incretin-based therapies and cardiovascular risk.
    Mannucci E; Dicembrini I
    Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing outcomes with incretin-based therapies: practical information for nurse practitioners to share with patients.
    Fleury-Milfort E
    J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():642-50. PubMed ID: 19900195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond glycemic control: treating the entire type 2 diabetes disorder.
    Brunton S
    Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.